---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-042182"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T05:58:41.469387+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MedTech Acquisition amends merger with TriSalus to assume restricted stock unit awards

## Summary
- Amendment allows MTAC to assume TriSalus' outstanding RSUs, converting them into MTAC RSUs at the Exchange Ratio.
- RSU conversion: number of MTAC shares = TriSalus RSU shares × Exchange Ratio, rounded down.
- Definition of Acquiror Transaction Expenses revised to exclude certain fees from Future PIPE Investment.
- Company acknowledges that grant of Company RSUs does not breach representations or warranties.
- No other changes to the Merger Agreement; all other terms remain in full force.

## SEC filing metadata
- accession: 0001104659-23-042182
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465923042182/0001104659-23-042182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465923042182/tm2311821d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-042182
- JSON: https://secwatch.observer/filing/0001104659-23-042182.json
- Plain text: https://secwatch.observer/filing/0001104659-23-042182.txt

## Key facts
- Material Agreements
  TriSalus Life Sciences, Inc. amended Amendment to Agreement and Plan of Merger with TriSalus Life Sciences, Inc. valued at Amendment to provide for assumption by MTAC of TriSalus' restricted stock unit awards outstanding pr (effective 2023-04-04).
  - Action: amendment
  - Agreement: merger
  - Counterparty: TriSalus Life Sciences, Inc.
  - Value: Amendment to provide for assumption by MTAC of TriSalus' restricted stock unit awards outstanding pr
  - Effective: 2023-04-04
  source text: On April 4, 2023, MTAC, Merger Sub, and TriSalus amended the Merger Agreement (the “ Amendment ”) to, among other matters, provide for the assumption by MTAC of any restricted stock unit awards under TriSalus’ existing equity plan that are outstanding as of immediately prior to the closing of the Business Combination, which will be converted into restricted stock unit awards covering shares of Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923042182/0001104659-23-042182-index.htm
- Material Agreements
  TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with TriSalus Life Sciences, Inc. valued at Merger of Merger Sub into TriSalus, TriSalus surviving as wholly owned subsidiary of MTAC, TriSalus (effective 2022-11-11).
  - Action: entry
  - Agreement: merger
  - Counterparty: TriSalus Life Sciences, Inc.
  - Value: Merger of Merger Sub into TriSalus, TriSalus surviving as wholly owned subsidiary of MTAC, TriSalus
  - Effective: 2022-11-11
  source text: On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock, par value $0.0001 per share (the “ Common Stock ” and the transactions contemplated by the Merger Agreement and the related ancillary agreements, the “ Business Combination ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923042182/0001104659-23-042182-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.